Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eplerenone crystalline form exhibiting enhanced dissolution rate

A technology of eplerenone and crystal form, which is applied in the preparation of steroids, medical preparations containing active ingredients, drug combinations, etc., and can solve problems such as gynecomastia

Inactive Publication Date: 2004-06-09
PHARMACIA CORP
View PDF42 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, spironolactone has antiandrogenic activity and may cause gynecomastia and impotence in men

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eplerenone crystalline form exhibiting enhanced dissolution rate
  • Eplerenone crystalline form exhibiting enhanced dissolution rate
  • Eplerenone crystalline form exhibiting enhanced dissolution rate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0365] Embodiment 1: prepare butanone compound by high-purity eplerenone raw material and prepare by this solvate Eplerenone Crystalline Form L

[0366] A. Preparation of Butanone Compounds

[0367] Under magnetic stirring at 900 rpm, 437 mg of high-purity eplerenone (purity > 99%, and the total content of diepoxide and 11,12-epoxide < 0.2%) was dissolved by heating to boiling on a hot plate. In 10ml butanone. Under continuous magnetic stirring, the resulting solution was cooled to room temperature. Once at room temperature, the solution was transferred to a 1°C bath and stirring was continued for 1 hour. The butanate solid was collected from the cold solution by vacuum filtration.

[0368] B. Preparation of eplerenone crystalline form L

[0369] The butanate solid prepared as described above was dried in an oven at 100° C. under normal pressure for 4 hours. The dried solid was confirmed to be pure Form L by DSC and XRPD analysis.

Embodiment 2

[0370] Example 2: Preparation of additional solvates from high-purity starting materials

[0371] According to substantially the same method as in Example 1, the following solvents were used instead of butanone to prepare additional solvates: n-propanol, 2-pentanone, acetic acid, acetone, butyl acetate, chloroform, ethanol, isobutanol , isobutyl acetate, isopropanol, methyl acetate, ethyl propionate, n-butanol, n-octanol, propyl acetate, propylene glycol, tert-butanol, tetrahydrofuran, and toluene.

Embodiment 3

[0372] Example 3: Preparation of Butanone Compounds by Vapor Diffusion Growth

[0373] A stock solution was formed by dissolving 400 mg of eplerenone (>99.9% purity) in 20 ml of methyl ethyl ketone by warming on a hot plate. 8 ml of this stock solution was diluted to 10 ml with butanone, and the resulting solution was referred to as an 80% diluted sample. 4 ml of this stock solution was diluted to 10 ml with butanone (40% diluted sample). 2 ml of this stock solution was diluted to 10 ml with butanone (20% diluted sample). Each diluted sample in a 20 ml scintillation vial was transferred to a dry jar containing a small amount of hexane as an anti-solvent. The dry jar was sealed and the hexane vapor was allowed to diffuse into the butanone solution. Crystals of eplerenone butanate grew in 80% of the diluted samples within 24 hours.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having relatively hich physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and / or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.

Description

field of invention [0001] The present invention relates to pharmaceutically active agents which are aldosterone receptor antagonists, more particularly the present invention relates to the aldosterone receptor antagonist eplerenone. In particular, the present invention relates to a new crystalline form of eplerenone, a method for preparing the crystalline form, a pharmaceutical composition comprising the crystalline form, the use of the crystalline form for the treatment and / or prevention of aldosterone-mediated disorders and / or diseases, including Process for a plethora of related disorders and diseases such as hypertension, and the use of the crystalline form for the preparation of medicaments. Background of the invention [0002] The compound 9,11-epoxy-17-hydroxy-3-oxopregna-4-ene-7,21-dicarboxylate hydrogen methyl ester, γ-lactone, having structure (I) and called eplerenone was reported for the first time In US Pat. No. 4,559,332 to Grob et al., the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P1/16A61P9/04A61P9/12A61P43/00C07J71/00C07J75/00
CPCC07J71/0015A61P1/16A61P13/08A61P25/24A61P43/00A61P9/04A61P9/12A61K31/585
Inventor K·巴顿T·B·波尔查德特M·V·卡洛斯S·德赛L·J·菲罗H·T·戈德S·甘泽C·R·利特勒P·S·穆迪帕利M·A·皮茨D·R·皮利保斯卡斯Y·-L·L·邢G·L·斯塔尔J·J·维佐雷克C·Y·彦
Owner PHARMACIA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com